As previously announced, Waldencast’s (WALD) Board of Directors is conducting a comprehensive review of a broad range of strategic alternatives focused on maximizing shareholder value. To support the evaluation of all potential pathways, the Board has retained Lazard as financial advisor. As part of this review and aligned with our objective to strengthen our balance sheet and sharpen our strategic focus, the Company executed the sale of the Obagi Japan trademark rights. The Company does not intend to comment further on the status or timing of this process unless and until the Board approves a definitive course of action or determines that additional disclosure is appropriate. Given the broad scope of the review, there can be no assurance that it will result in a transaction or any other specific outcome.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast reports Q2 revenue $66.8M vs. $63.3M last year
- Waldencast’s Obagi Medical to present new data at ASDS annual meeting
- Waldencast Enhances Financial Position with Trademark Sale and New Credit Facility
- Waldencast sells rights to the ‘Obagi’ trademark in Japan to Rohto for $82.5M
- Is WALD a Buy, Before Earnings?